Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Charles Daley to Anti-Bacterial Agents

This is a "connection" page, showing publications Charles Daley has written about Anti-Bacterial Agents.

 
Connection Strength
  
 
 
6.615
  
  1. Daley CL, van Ingen J, Chalmers JD, Flume PA, Griffith DE, Hasegawa N, Morimoto K, Winthrop KL, Sheu CC, Avsar K, Andrisani D, Codecasa LR, Terschlüsen E, May D, Yuen DW, Wu P, Hassan M, Nevoret ML, Mange K. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial. Ann Am Thorac Soc. 2026 Apr 01; 23(4):536-547.
    View in: PubMed
    Score: 0.448
  2. Daley CL, Flume PA, van Ingen J, Khare R, Mingora CM, Nguyen MH, Winthrop KL, Zha BS. A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria. Eur Respir Rev. 2025 Oct; 34(178).
    View in: PubMed
    Score: 0.436
  3. Morimoto K, Daley CL. Comprehensive Management Algorithm for Mycobacterium avium Complex Pulmonary Disease in the Real-World Setting. Ann Am Thorac Soc. 2025 05; 22(5):651-659.
    View in: PubMed
    Score: 0.420
  4. Nguyen MH, Calado Nogueira de Moura V, Keepers TR, van Ingen J, Daley CL. In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution. J Antimicrob Chemother. 2025 Mar 03; 80(3):713-716.
    View in: PubMed
    Score: 0.416
  5. Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2022 01; 161(1):64-75.
    View in: PubMed
    Score: 0.324
  6. Daley CL, Winthrop KL. Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management. J Infect Dis. 2020 08 20; 222(Suppl 4):S199-S211.
    View in: PubMed
    Score: 0.304
  7. Koh WJ, Jeong BH, Jeon K, Park HY, Kim SY, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2015 Aug; 59(8):4994-6.
    View in: PubMed
    Score: 0.211
  8. Daley CL, Glassroth J. Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain. Ann Am Thorac Soc. 2014 Jan; 11(1):96-7.
    View in: PubMed
    Score: 0.192
  9. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012 Dec; 56(12):6324-7.
    View in: PubMed
    Score: 0.176
  10. Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant. 2009 Dec; 14(6):619-24.
    View in: PubMed
    Score: 0.144
  11. Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med. 2008 Oct; 29(5):569-76.
    View in: PubMed
    Score: 0.133
  12. Poonawala H, Davis K, Kenny ME, Alivisatos A, Van N, Washington T, Calado Nogueira de Moura V, Daley CL, Aldridge BB. Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. Antimicrob Agents Chemother. 2026 05 06; 70(5):e0187625.
    View in: PubMed
    Score: 0.112
  13. Moreira-Sousa D, Martins B, Aguiar A, Pinheiro M, Akkerman OW, Aksamit TR, Aliberti S, Andrejak C, Daley CL, van Ingen J, Lange C, Lipman M, Loebinger MR, Jankovic Makek M, Morimoto K, Thomson R, Wagner D, Winthrop KL, Yim JJ, Duarte R. Management of nontuberculous mycobacterial Pulmonary disease refractory to guideline-based therapy: A systematic review. Pulmonology. 2026 Dec; 32(1):2632467.
    View in: PubMed
    Score: 0.111
  14. Dousa KM, Shin E, Kurz SG, Rubin EJ, Holland SM, Olivier KN, Daley CL, Kreiswirth BN, Pottinger PS, Bonomo RA. The Role of ß-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. Clin Infect Dis. 2026 Feb 09; 82(1):e135-e145.
    View in: PubMed
    Score: 0.111
  15. Moreira-Sousa D, Martins B, Aguiar A, Pinheiro M, Akkerman O, Aksamit TR, Aliberti S, Andrejak C, Daley CL, van Ingen J, Lange C, Lipman M, Loebinger MR, Jankovic Makek M, Morimoto K, Thomson RM, Wagner D, Winthrop KL, Yim JJ, Duarte R. Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2026 Jan; 67(1).
    View in: PubMed
    Score: 0.110
  16. Singh S, Boorgula GD, Nguyen MH, Daley CL, Gumbo T, Srivastava S. Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease. J Antimicrob Chemother. 2026 Jan 06; 81(1).
    View in: PubMed
    Score: 0.110
  17. Nguyen MH, Plattner M, Verma D, Krishnamurthy RV, Xie M, Calado Nogueira de Moura V, Haldimann K, Lang R, Becker K, Kaur P, Shandil RK, Singh M, Bulman ZP, Dick T, Narayanan S, Schulthess B, Mitarai S, Daley CL, Hobbie SN. Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria. EBioMedicine. 2026 Jan; 123:106103.
    View in: PubMed
    Score: 0.110
  18. Singh N, Dangi B, Johnson JJ, Louie A, Karunanidhi A, Curry BN, Mitarai S, Daley CL, Hobbie SN, Bulman ZP. Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model. J Antimicrob Chemother. 2025 May 02; 80(5):1309-1314.
    View in: PubMed
    Score: 0.105
  19. Nguyen MH, Haas MK, Kasperbauer SH, Calado Nogueira de Moura V, Eddy JJ, Mitchell JD, Khare R, Griffith DE, Chan ED, Daley CL. Executive Summary: State-of-the-Art Review: Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024 10 15; 79(4):805-806.
    View in: PubMed
    Score: 0.101
  20. Nguyen MH, Haas MK, Kasperbauer SH, Calado Nogueira de Moura V, Eddy JJ, Mitchell JD, Khare R, Griffith DE, Chan ED, Daley CL. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024 10 15; 79(4):e27-e47.
    View in: PubMed
    Score: 0.101
  21. Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, Taracila MA, Nguyen DC, Kreiswith BN, Daley CL, Remy KE, Holland SM, Bonomo RA. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024 06 12; 15(6):e0060924.
    View in: PubMed
    Score: 0.098
  22. Chen L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, Daley CL, Kreiswirth BN. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2024 05 02; 68(5):e0017424.
    View in: PubMed
    Score: 0.098
  23. Nguyen MH, Daley CL. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start? Clin Chest Med. 2023 12; 44(4):771-783.
    View in: PubMed
    Score: 0.093
  24. Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ, Jhun BW. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest. 2021 08; 160(2):436-445.
    View in: PubMed
    Score: 0.079
  25. Flume PA, Griffith DE, Chalmers JD, Daley CL, Olivier K, O'Donnell A, Aksamit T, Kasperbauer S, Leitman A, Winthrop KL. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2021 02; 159(2):537-543.
    View in: PubMed
    Score: 0.076
  26. Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, Ki CS, Shin SY, Jhun BW, Shin SJ, Daley CL, Koh WJ, Lee NY. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. J Clin Microbiol. 2019 08; 57(8).
    View in: PubMed
    Score: 0.070
  27. Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother. 2019 08; 63(8).
    View in: PubMed
    Score: 0.070
  28. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 07; 54(1).
    View in: PubMed
    Score: 0.070
  29. Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev Respir Med. 2019 09; 13(9):851-861.
    View in: PubMed
    Score: 0.070
  30. Kim SY, Moon SM, Jhun BW, Kwon OJ, Huh HJ, Lee NY, Lee SH, Shin SJ, Kasperbauer SH, Huitt GA, Daley CL, Koh WJ. Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 06; 63(6).
    View in: PubMed
    Score: 0.070
  31. Moon SM, Jhun BW, Baek SY, Kim S, Jeon K, Ko RE, Shin SH, Lee H, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med. 2019 05; 151:1-7.
    View in: PubMed
    Score: 0.069
  32. Kasperbauer SH, Daley CL. Mycobacterium chimaera Infections Related to the Heater-Cooler Unit Outbreak: A Guide to Diagnosis and Management. Clin Infect Dis. 2019 03 19; 68(7):1244-1250.
    View in: PubMed
    Score: 0.069
  33. Kim SY, Jhun BW, Moon SM, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagn Microbiol Infect Dis. 2019 May; 94(1):38-40.
    View in: PubMed
    Score: 0.067
  34. Jhun BW, Kim SY, Moon SM, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2018 11 15; 198(10):1322-1330.
    View in: PubMed
    Score: 0.067
  35. Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, Kwon OJ, Ahn J, Moon IJ, Shin SJ, Daley CL, Koh WJ. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Antimicrob Agents Chemother. 2018 07; 62(7).
    View in: PubMed
    Score: 0.065
  36. Jhun BW, Moon SM, Kim SY, Park HY, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Koh WJ. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2018 02; 62(2).
    View in: PubMed
    Score: 0.064
  37. Choi H, Jhun BW, Kim SY, Kim DH, Lee H, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. Diagn Microbiol Infect Dis. 2018 Apr; 90(4):293-295.
    View in: PubMed
    Score: 0.063
  38. Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Kim H, Kwon OJ. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 09; 50(3).
    View in: PubMed
    Score: 0.062
  39. Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin S, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 10; 61(10).
    View in: PubMed
    Score: 0.062
  40. Daley CL. Mycobacterium avium Complex Disease. Microbiol Spectr. 2017 04; 5(2).
    View in: PubMed
    Score: 0.060
  41. Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
    View in: PubMed
    Score: 0.060
  42. Choi H, Kim SY, Lee H, Jhun BW, Park HY, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease. Antimicrob Agents Chemother. 2017 02; 61(2).
    View in: PubMed
    Score: 0.059
  43. Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, Lee H, Park HY, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Kim H, Kwon OJ. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis. 2017 Feb 01; 64(3):309-316.
    View in: PubMed
    Score: 0.058
  44. Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 11; 60(11):6758-6765.
    View in: PubMed
    Score: 0.058
  45. Jeong BH, Jeon K, Park HY, Moon SM, Kim SY, Lee SY, Shin SJ, Daley CL, Koh WJ. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 10; 60(10):6076-83.
    View in: PubMed
    Score: 0.058
  46. Henkle E, Aksamit T, Barker A, Daley CL, Griffith D, Leitman P, Leitman A, Malanga E, Marras TK, Olivier KN, Prevots DR, Prieto D, Quittner AL, Skach W, Walsh JW, Winthrop KL. Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Ann Am Thorac Soc. 2016 09; 13(9):S379-84.
    View in: PubMed
    Score: 0.058
  47. Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. Chest. 2016 Dec; 150(6):1222-1232.
    View in: PubMed
    Score: 0.057
  48. Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler AM, Menon LR, Bamrah Morris S, Brostrom R, Chorba T, Peloquin CA. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J. 2016 Apr; 35(4):414-21.
    View in: PubMed
    Score: 0.056
  49. Czaja CA, Levin AR, Cox CW, Vargas D, Daley CL, Cott GR. Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study. Ann Am Thorac Soc. 2016 Jan; 13(1):40-8.
    View in: PubMed
    Score: 0.055
  50. Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015 Apr; 45(4):1177-9.
    View in: PubMed
    Score: 0.052
  51. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015 Jan 01; 191(1):96-103.
    View in: PubMed
    Score: 0.051
  52. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011 Mar 01; 52(5):565-71.
    View in: PubMed
    Score: 0.039
  53. Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004 Oct 01; 170(7):793-8.
    View in: PubMed
    Score: 0.025
  54. Dartois V, Bonfield TL, Boyce JP, Daley CL, Dick T, Gonzalez-Juarrero M, Gupta S, Kramnik I, Lamichhane G, Laughon BE, Lorè NI, Malcolm KC, Olivier KN, Tuggle KL, Jackson M. Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations. Tuberculosis (Edinb). 2024 07; 147:102503.
    View in: PubMed
    Score: 0.024
  55. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003 Dec 15; 188(12):1878-84.
    View in: PubMed
    Score: 0.024
  56. Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, Daley CL, Khare R. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. J Antimicrob Chemother. 2023 12 01; 78(12):2849-2858.
    View in: PubMed
    Score: 0.024
  57. Hunkins JJ, de-Moura VC, Eddy JJ, Daley CL, Khare R. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis. 2023 Mar; 105(3):115882.
    View in: PubMed
    Score: 0.022
  58. Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, Malcolm KC, Epperson LE, Hasan NA, Hendrix J, Callahan K, Walton K, Vestal B, Wheeler E, Rysavy NM, Poch K, Caceres S, Lovell VK, Hisert KB, de Moura VC, Chatterjee D, De P, Weakly N, Martiniano SL, Lynch DA, Daley CL, Strong M, Jia F, Hatfull GF, Davidson RM. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 05 26; 185(11):1860-1874.e12.
    View in: PubMed
    Score: 0.021
  59. Dousa KM, Nguyen DC, Kurz SG, Taracila MA, Bethel CR, Schinabeck W, Kreiswirth BN, Brown ST, Boom WH, Hotchkiss RS, Remy KE, Jacono FJ, Daley CL, Holland SM, Miller AA, Bonomo RA. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane ß-Lactamase Inhibitor To Augment ß-Lactam Action. mBio. 2022 02 22; 13(1):e0352921.
    View in: PubMed
    Score: 0.021
  60. Davidson RM, Hasan NA, Epperson LE, Benoit JB, Kammlade SM, Levin AR, Calado de Moura V, Hunkins J, Weakly N, Beagle S, Sagel SD, Martiniano SL, Salfinger M, Daley CL, Nick JA, Strong M. Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers. Ann Am Thorac Soc. 2021 12; 18(12):1960-1969.
    View in: PubMed
    Score: 0.021
  61. Nguyen DC, Dousa KM, Kurz SG, Brown ST, Drusano G, Holland SM, Kreiswirth BN, Boom WH, Daley CL, Bonomo RA. "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clin Infect Dis. 2021 10 20; 73(8):1532-1536.
    View in: PubMed
    Score: 0.021
  62. Marras SAE, Chen L, Shashkina E, Davidson RM, Strong M, Daley CL, Kreiswirth BN. A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility. J Clin Microbiol. 2021 07 19; 59(8):e0045521.
    View in: PubMed
    Score: 0.020
  63. Martiniano SL, Wagner BD, Brennan L, Wempe MF, Anderson PL, Daley CL, Anthony M, Nick JA, Sagel SD. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. J Cyst Fibros. 2021 09; 20(5):772-778.
    View in: PubMed
    Score: 0.020
  64. Dousa KM, Kurz SG, Taracila MA, Bonfield T, Bethel CR, Barnes MD, Selvaraju S, Abdelhamed AM, Kreiswirth BN, Boom WH, Kasperbauer SH, Daley CL, Bonomo RA. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrob Agents Chemother. 2020 07 22; 64(8).
    View in: PubMed
    Score: 0.019
  65. Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2019 05; 53(5).
    View in: PubMed
    Score: 0.017
  66. Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. Am J Respir Crit Care Med. 2019 04 15; 199(8):947-951.
    View in: PubMed
    Score: 0.017
  67. Koh WJ, Jeong BH, Jeon K, Kim SY, Park KU, Park HY, Huh HJ, Ki CS, Lee NY, Lee SH, Kim CK, Daley CL, Shin SJ, Kim H, Kwon OJ. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Chest. 2016 Dec; 150(6):1211-1221.
    View in: PubMed
    Score: 0.014
  68. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016 Jan; 71 Suppl 1:i1-22.
    View in: PubMed
    Score: 0.014
  69. Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, Jeong BH, Jeon K, Koh WJ. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012 Nov 01; 186(9):917-25.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)